Literature DB >> 9952070

Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating.

D Feifel1, T Reza.   

Abstract

Oxytocin plays an important role in the regulation of normal cognitive functions and behaviors, which are disturbed in schizophrenia. Several studies suggest that oxytocinergic function is abnormal in schizophrenia patients. Thus, oxytocin may be involved in the pathophysiology associated with this disorder. This study investigated the regulatory effects of oxytocin on deficits in prepulse inhibition (PPI) associated with schizophrenia. Prepulse inhibition (PPI) is an operational measure of sensorimotor gating which can be measured across many species. PPI is the normal suppression of the startle reflex when the intense startling stimulus ("pulse") is immediately preceded by a weaker stimulus ("prepulse"). Subcutaneously administered oxytocin (0.04-1.0 mg/kg) dose-dependently restored PPI that had been reduced in rats by dizocilpine, a non-competitive NMDA antagonist, and by amphetamine, an indirect dopamine agonist. Oxytocin did not produce a significant effect on baseline PPI or PPI decreased by the direct dopamine agonist, apomorphine. The underlying startle response amplitude was also not significantly altered by oxytocin. These results suggest that oxytocin may play an important role in the modulation of dopaminergic and glutamatergic regulation of PPI, and that it may act as a novel endogenous antipsychotic.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9952070     DOI: 10.1007/s002130050811

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  38 in total

1.  Oxytocin as a potential therapeutic target for schizophrenia and other neuropsychiatric conditions.

Authors:  David Feifel
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

2.  Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications.

Authors:  Robert H Ring; Jessica E Malberg; Lisa Potestio; Julia Ping; Steve Boikess; Bin Luo; Lee E Schechter; Stacey Rizzo; Zia Rahman; Sharon Rosenzweig-Lipson
Journal:  Psychopharmacology (Berl)       Date:  2006-01-18       Impact factor: 4.530

Review 3.  Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward.

Authors:  Ellen R Bradley; Joshua D Woolley
Journal:  Neurosci Biobehav Rev       Date:  2017-05-12       Impact factor: 8.989

4.  Oxytocin in schizophrenia: a review of evidence for its therapeutic effects.

Authors:  Kai Macdonald; David Feifel
Journal:  Acta Neuropsychiatr       Date:  2011-12-19       Impact factor: 3.403

5.  Testing synaptic plasticity in dynamic mate choice decisions: N-methyl D-aspartate receptor blockade disrupts female preference.

Authors:  Mary E Ramsey; Wendy Vu; Molly E Cummings
Journal:  Proc Biol Sci       Date:  2014-05-07       Impact factor: 5.349

6.  DNA damage after chronic oxytocin administration in rats: a safety yellow light?

Authors:  Daniela D Leffa; Francine Daumann; Adriani P Damiani; Arlindo C Afonso; Maria A Santos; Thayara H Pedro; Renan P Souza; Vanessa M Andrade
Journal:  Metab Brain Dis       Date:  2016-08-03       Impact factor: 3.584

Review 7.  Neurobiology of sociability.

Authors:  Heather K Caldwell
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 8.  Empathy as a Concept from Bench to Bedside: A Translational Challenge.

Authors:  Nazan Uysal; Ulaş M Çamsari; Mehmet ATEş; Sevim Kandİş; Aslı Karakiliç; Gamze B Çamsari
Journal:  Noro Psikiyatr Ars       Date:  2019-11-28       Impact factor: 1.339

9.  Mechanisms underlying sexual and affiliative behaviors of mice: relation to generalized CNS arousal.

Authors:  Deborah N Shelley; Elena Choleris; Martin Kavaliers; Donald W Pfaff
Journal:  Soc Cogn Affect Neurosci       Date:  2006-12       Impact factor: 3.436

10.  Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor.

Authors:  Linnet Ramos; Callum Hicks; Richard Kevin; Alex Caminer; Rajeshwar Narlawar; Michael Kassiou; Iain S McGregor
Journal:  Neuropsychopharmacology       Date:  2013-05-16       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.